Issue

Vol. 66 No. 8: Issue 8

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo

https://doi.org/10.14715/cmb/2017.63.11.16
Xuewen Xiang
Department of Obstetrics, Jiaozhou Central Hospital, Qingdao 266300, China
Fang Wang
Department of Obstetrics, Jiaozhou Central Hospital, Qingdao 266300, China
Ni Zhao
Department of Obstetrics, Jiaozhou Central Hospital, Qingdao 266300, China
Zhao Zhou
Department of Obstetrics, Jiaozhou Central Hospital, Qingdao 266300, China

Corresponding Author(s) : Zhao Zhou

zhouzhaoiio@163.com

Cellular and Molecular Biology, Vol. 66 No. 8: Issue 8

Abstract

This study aimed to evaluate the maternal and fetal results in women undergoing antihypertensive therapy (low aspirin or labetalol) with mild to severe chronic hypertension relative to women without medicines. This randomized multi-center clinical trial was performed with random division into three groups of 393 pregnant women with mild to moderate chronic hypertension. From the beginning of the pregnancy to the end of the puerperium, the low dosage aspirin group (n = 129), the labetalol group (n = 127), and the drug-free or control group (n = 126) reported both mother and child results. Major variations in the presence of severely motherly hypertension, pre-eclampsia, renal failure, ECG shifts, and cardiovascular rupture between treatment groups (low doses of aspirin and labetalol) and control groups were noted. Repeated placenta and blood pressure control hospitalizations. (P<0.001) in the control group more often (untreated). The new babies were more vulnerable to gestational age (SGA), neonatal hypotension, neonatal Hyperbilirubinemia, and ICU (p <0.001 in contrast with the low-dose aspirin and control groups). In the control group, the proportion of premature babies was considerably higher than in the treatment group (p<0,05). A mild to moderate persistent high blood pressure during pregnancy therapy helps minimize mother and child occurrence. The use of labetalol is correlated with a higher incidence of SGA, neonatal hypotension, and neonatal hyperbilirubinemia relative to low-dose aspirin or control group.

Keywords

Pregnancy-induced hypertension labetalol low dose aspirin placebo metabolic changes
Xiang, X., Wang, F., Zhao, N., & Zhou, Z. (2020). Treatment of pregnancy-induced hypertension compared with labetalol, low dose aspirin and placebo. Cellular and Molecular Biology, 66(8), 9–13. https://doi.org/10.14715/cmb/2017.63.11.16
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Gongora MC, Wenger NK. Cardiovascular complications of pregnancy. Int J Mol Sci 2015; 16(10): 23905-23928.
  2. Flack JM, Peters R, Mehra VC, Nasser SA. Hypertension in special populations. Cardiol Clin 2002; 20(2): 303-319, vii.
  3. Mustafa R, Ahmed S, Gupta A, Venuto RC. A comprehensive review of hypertension in pregnancy. J Pregnancy 2012; 2012.
  4. Ahmad A, Samuelsen S. Hypertensive disorders in pregnancy and fetal death at different gestational lengths: a population study of 2 121 371 pregnancies. BJOG: Int J Obstet Gynecol 2012; 119(12): 1521-1528.
  5. Lindheimer M, Taler S, Cunningham F. ASH position article: hypertension in pregnancy. J Am Soc Hypertens 2010; 4: 68-78.
  6. Say L, Chou D, Gemmill A et al. Global causes of maternal death: a WHO systematic analysis. Lancet Global Health 2014; 2(6): e323-e333.
  7. Folic M, Folic N, Varjacic M, Jakovljevic M, Jankovic S. Antihypertensive drug therapy for hypertensive disorders in pregnancy. Acta Med Medianae 2008; 47(3): 65-72.
  8. Kuklina EV, Ayala C, Callaghan WM. Hypertensive disorders and severe obstetric morbidity in the United States. Obstet Gynecol 2009; 113(6): 1299-1306.
  9. Hou Y, Yun L, Zhang L, Lin J, Xu R. A risk factor-based predictive model for new-onset hypertension during pregnancy in Chinese Han women. BMC Cardiovasc Disord 2020; 20: 1-10.
  10. Kobashi G. Genetic and environmental factors associated with the development of hypertension in pregnancy. J Epidemiol 2006; 16(1): 1-8.
  11. Rudman SS, Mustapic M, Kosec V, Pivac N, Rudman F, Muck-Seler D. Serotonin risk factors for the development of hypertension in pregnancy. Arch Gynecol Obstet 2015; 291(4): 779-785.
  12. Shao Y, Yao Y, Chen Y et al. Efficacy of magnesium sulfate combined with labetalol for treatment of gestational hypertension and its effects on pregnancy outcome: a meta-analysis. J Shenyang Med College 2019; (4): 3.
  13. Gilbert WM, Young AL, Danielsen B. Pregnancy outcomes in women with chronic hypertension: a population-based study. J Reprod Med 2007; 52(11): 1046-1051.
  14. Seely EW, Ecker J. Clinical practice. Chronic hypertension in pregnancy. N Engl J Med Overseas Ed 2011; 365(5): 439-446.
  15. Rezk M, Ellakwa H, Gamal A, Emara M. Maternal and fetal morbidity following discontinuation of antihypertensive drugs in mild to moderate chronic hypertension: A 4-year observational study. Pregnancy Hypertension: Int J Women's Cardiovasc Health 2016; 6(4): 291-294.
  16. Vasapollo B, Novelli GP, Gagliardi G, Farsetti D, Valensise H. Pregnancy complications in chronic hypertensive patients are linked to pre-pregnancy maternal cardiac function and structure. Am J Obstet Gynecol 2020.
  17. Magee L, Group CS, von Dadelszen P et al. Do labetalol and methyldopa have different effects on pregnancy outcome? Analysis of data from the Control of Hypertension In Pregnancy Study (CHIPS) trial. BJOG: Int J Obstet Gynaecol 2016; 123(7): 1143-1151.
  18. Rezk M, Ellakwa H, Gamal A, Emara M. Maternal and fetal morbidity following discontinuation of antihypertensive drugs in mild to moderate chronic hypertension: A 4-year observational study. Pregnancy Hypertens 2016; 6(4): 291-294.
  19. Waitz M, Nusser S, Schmid MB, Dreyhaupt J, Reister F, Hummler H. Risk factors associated with intraventricular hemorrhage in preterm infants with≤ 28 weeks gestational age. Klinische Pädiatrie 2016; 228(05): 245-250.
  20. Molvi SN, Mir S, Rana VS, Jabeen F, Malik AR. Role of antihypertensive therapy in mild to moderate pregnancy-induced hypertension: a prospective randomized study comparing labetalol with alpha methyldopa. Arch Gynecol Obstet 2012; 285(6): 1553-1562.
  21. Magee LA, Rey E, Asztalos E et al. Management of non-severe pregnancy hypertension–A summary of the CHIPS Trial (Control of Hypertension in Pregnancy Study) research publications. Pregnancy Hypertension 2019; 18: 156-162.
  22. LeFevre N, Krumm E. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Am Family Physic 2019; 100(7): 403-405.
  23. Heida KY, Zeeman GG, Van Veen TR, Hulzebos CV. Neonatal side effects of maternal labetalol treatment in severe preeclampsia. Early human development Jul 2012; 88(7): 503-507.
  24. Coomarasamy A, Honest H, Papaioannou S, Gee H, Khan KS. Aspirin for prevention of preeclampsia in women with historical risk factors: a systematic review. Obstet Gynecol 2003; 101(6): 1319-1332.
  25. Moore GS, Allshouse AA, Post AL, Galan HL, Heyborne KD. Early initiation of low-dose aspirin for reduction in preeclampsia risk in high-risk women: a secondary analysis of the MFMU High-Risk Aspirin Study. J Perinatol 2015; 35(5): 328-331.
  26. Giannubilo SR, Bezzeccheri V, Cecchi S et al. Nifedipine versus labetalol in the treatment of hypertensive disorders of pregnancy. Arch Gynecol Obstet 2012; 286(3): 637-642.
  27. el-Qarmalawi AM, Morsy AH, al-Fadly A, Obeid A, Hashem M. Labetalol vs. methyldopa in the treatment of pregnancy-induced hypertension. Int J Gynaecol Obstet 1995; 49(2): 125-130.
  28. Pentareddy MR, Shailendra D, Prasuna G, Subbaratnam Y, Naresh D, Katta R. Safety and efficacy of methyldopa and labetalol in controlling blood pressure in hypertensive disorders of pregnancy. Int J Basic Clinic Pharmacol 2017; 6(4): 942-947.
  29. Kazemi E, Zargooshi J Kaboudi M, Heidari P, Kahrizi D, Mahaki B, Mohammadian Y, Khazaei H, Ahmed K. A genome-wide association study to identify candidate genes for erectile dysfunction. Brief Bioinform 2020; bbaa338, https://doi.org/10.1093/bib/bbaa338.
  30. Maheshwari N, Wagh R, Sharma S, Mutalik M, Gupta M, Siddiqui W. Role of labetalol and methyldopa in newly diagnosed mild hypertension in pregnancy: a prospective drug comparative study in a rural tertiary care hospital in India. Int J Pharm Sci Res 2017; 8(1): 226.
  31. Lin J, Wang Y, Wei X, Kong S, Liu Z, Liu J, Zhang F, Lin S, Ji B, Zhou Z, Guo Z. Controllable antibacterial and bacterially anti-adhesive surface fabricated by a bio-inspired beetle-like macromolecule. Int J Biol Macromol 2020. Doi: 10.1016/j.ijbiomac.2020.04.207.
  32. Zhang J, Liu B. A review on the recent developments of sequence-based protein feature extraction methods. Curr Bioinform 2019;14(3):190-9. Doi: 10.2174/1574893614666181212102749.
  33. Xu L, Jiang S, Zou Q. An in silico approach to identification, categorization and prediction of nucleic acid binding proteins. bioRxiv. 2020. Doi: 10.1093/bib/ bbaa171.
  34. Zhu S, Wang X, Zheng Z, Zhao XE, Bai Y, Liu H. Synchronous measuring of triptolide changes in rat brain and blood and its application to a comparative pharmacokinetic study in normal and Alzheimer's disease rats. J Pharmaceutic Biomed Anal 2020;113263. Doi: 10.1016/j.jpba.2020.113263.
  35. Zhu S, Zheng Z, Peng H, Sun J, Zhao XE, Liu H. Quadruplex stable isotope derivatization strategy for the determination of panaxadiol and panaxatriol in foodstuffs and medicinal materials using ultra high performance liquid chromatography tandem mass spectrometry. J Chromatogr A. 2020; 1616:460794. Doi: 10.1016/j.chroma.2019.460794.
  36. Chen G, Li Y, Ren Z, Gu Y, Tang F, Mao J, Zhu J, Wang L, Li Y. Clinical Significance of MicroRNA-155-Regulated Autophagy and Apoptosis by Targeting Rictor/Fos in Gastric Cancer Progression. Nanosci Nanotechnol Lett 2020; 12(4):525-35.
  37. Alkhudhayri AA, Wahab R, Siddiqui MA, Ahmad J. Selenium Nanoparticles Induce Cytotoxicity and Apoptosis in Human Breast Cancer (MCF-7) and Liver (HepG2) Cell Lines. Nanosci Nanotechnol Lett 2020; 12(3):324-30.
  38. Jin Y, Zhu H, Zhu H, Jin F, Shi C, Yang L, Qian J, Zhang S. Fluorouracil Nanoliposomes Promote Apoptosis of Human Gastric Cancer Xenografts in Nude Mice. Nanosci. Nanotechnol. Lett 2020; 12: 690–695.
  39. Zhang T, Su H, Xing Y, Zhang J, Xu D. Protective Mechanism of Lipid-Lowering Ketone and Self-Assembled OA Chitosan Nanoparticles on Insulin Oxidative Stress. Induced by High Fat in BRL-3A Cells. Nanosci. Nanotechnol. Lett 2020; 12: 715–719.
  40. Zhang D, Lu Z, Sun B. Highly Sensitive Gold Nanoparticle Polymerase Chain Reaction in the Detection of Anaplastic Lymphoma Kinase-Positive Gastric Cancer from a Biopsy Specimen. Nanosci. Nanotechnol. Lett 2020; 12(4):498-505.
  41. Bordbar M, Darvishzadeh R, Pazhouhandeh M, Kahrizi D. An overview of genome editing methods based on endonucleases. Mod Genet J 2020; 15(2): 75-92.
  42. Bai J, Guo T, Dong W, Song Y, Guo T, Cui M. Reduction of Breast Cancer Lymph Node Metastasis by Nano-Carbon Absorption of 5-Fluorouracil. Nanosci. Nanotechnol. Lett 2020; 12(3):407-12.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 1434 Download : 747